Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07021638

EMMVIES : Walking Training at Home in VIrtual Reality for Children With Chronic Illnesses Impacting Physical Health

Over the past 30 years, the prevalence of congenital or acquired chronic diseases in children has risen, affecting between 10 and 30% of them, or at least 100,000 children in France. Pathologies such as cerebral palsy (CP), neuromuscular diseases (NMD), obesity or congenital heart disease impact physical health by causing musculoskeletal, respiratory or cardiovascular deficiencies. These limitations influence their ability to participate in daily activities, affecting their quality of life and that of their families.To minimize these impacts, motor rehabilitation programs focusing on physical activity are proposed, but their effectiveness requires prolonged practice. However, these specific programs, often delivered in remote specialized centers, are difficult to access. Home programs have been developed to overcome these constraints. They enable children, with the support of their parents, to carry out therapeutic activities at home. Although their feasibility has been demonstrated, their effectiveness is relative. A multitude of protocols and tools have been tested, with no harmonization of practices.To support the implementation of home-based programs for children with CP or obesity, virtual reality has already been used, mainly on the basis of commercial solutions. This solution is therefore feasible and has proved relatively effective.With this in mind, and based on the user experience of children, parents and professionals, the investigators have initially co-developed with the French company EzyGain a connected treadmill specifically adapted to pediatric needs and the requirements of home programs. The AMY treadmill is a compact treadmill with on-board sensors and a safety system, communicating with a tablet application and a virtual reality headset.Taking into account the opportunities offered by this new technology, as well as building on the effects and features already known from home programs, the investigators have developed a new modality for home programs focusing on walking for children with CP, MNM and obesity, the EMMVIES program. The crucial step now is to investigate the feasibility, tolerance and clinical effects of this EMMVIES program.

Recruiting

Interested in participating?

Request Info

Key information

Age range

6 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Les Capucins

Angers, France

Location status: Recruiting

Location contact

Adélie CHRISTIAENS, MD

PRINCIPAL_INVESTIGATOR

Anthony COEHLO, MD

PRINCIPAL_INVESTIGATOR

Fabienn EMERIAU, MD

PRINCIPAL_INVESTIGATOR

Julien DURIGNEUX, MD

PRINCIPAL_INVESTIGATOR

Marion BEAUMESNIL, MD

PRINCIPAL_INVESTIGATOR

Mickaël DINOMAIS, MD

CONTACT

[email protected]

+ 33 2 41 35 52 67 ext. + 33

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient aged 6 to 17 years at date of inclusion;
  • Able to walk for 5 minutes on a treadmill with or without body weight support, with or without technical aids;
  • Be able to understand and play virtual reality games (immersive or non-immersive);
  • Be able to answer questionnaires;
  • Patient affiliated to or benefiting from a social security scheme;
  • Informed consent, dated and signed by parents or guardians (if minors), to participate in the study;
  • Included in a care program specific to their chronic condition for at least 6 months;
  • Meet the following criteria depending on the group:

PC group:

  • Diagnosis of CP
  • Functional level classified II or III according to the Gross Motor Function Classification System (GMFCS)
  • Rehabilitation goal: improvement of gait and/or gross motor function

OB group:

  • Overweight or obese, defined by a BMI above the IOTF-25 percentile
  • Aim to increase daily physical activity
  • No history of hip pathology

Group NM:

  • Diagnosis of one of the following neuromuscular pathologies: spinal muscular atrophy type 3, Duchenne disease, congenital myopathy or Charcot Marie Tooth.
  • Functional level of grade 2 to 6 on the Walton scale, or grade 3 to 7 on the Vignos scale
  • Rehabilitation goal: improvement of walking and/or gross motor skills

Exclusion criteria

  • Patients weighing over 100 kg (due to the technical constraints of using the AMY mat).
  • For children aged 6 to 11: in connection with the immersive virtual reality device: problems with stereoscopic vision (perception of images in 3 dimensions), unstabilized epilepsy, facial trauma < 3 months, hearing or visual impairment, pain, dizziness or nausea caused by using immersive virtual reality.
  • Patients who have undergone surgery in the last 3 months;
  • Patients who have received intramuscular botulinum toxin injections in the lower limbs or intensive therapy in the 3 months prior to inclusion;
  • Patient with a non-routine therapeutic program planned within 5 months that could lead to confusion with the tested program;
  • Patient with insufficient understanding of the French language;
  • Patient opposition (child or adolescent);
  • Persons deprived of liberty by judicial or administrative decision;
  • Persons under compulsory psychiatric care;
  • Persons under legal protection;

Treatment and study plan

EMMVIES program

Other

Walking Training at Home in VIrtual Reality for Children with Chronic Illnesses Impacting Physical Health

Primary outcomes

  1. Home rehabilitation program

    Time frame: 3 x 30-minute sessions over 10 weeks

    The treadmill walking training program comprises a minimum of 3 sessions per week, with one day of rest between each session. Each session comprises around 30 minutes of physical exercise on a mat, alternating between walking and balance exercises.

Secondary outcomes

  1. Assessment of lower limb muscle strength

    Time frame: Inclusion, 10 weeks and 20 weeks

    Muscle strength is measured using a wireless electronic hand dynamometer (DEM) (MicroFET 2) based on a standardized protocol used in clinical routine and performed on an examination table on the following muscle groups: plantar flexors (knee extended and flexed), knee flexors and extensors and hip abductors. The child is asked to contract each muscle group tested for 3 to 5 seconds, three times against the dynamometer held by an assessor. The average of the three peak pressures achieved for each muscle group tested is recorded. The estimated duration of these measurements is 15 minutes.

  2. 10-meter walk test

    Time frame: Inclusion, 10 weeks and 20 weeks

    Patients' gait quality is assessed using a minimal version of the Quantified Gait Analysis (QGA), which simply includes spatiotemporal, kinematic and electromyographic gait parameters. To this end, 10-meter barefoot walking tests at spontaneous (2 trials), fast (2 trials) and double-task speeds, i.e. walking and listing animal names (1 trial) and fruit names (1 trial), and finally with usual shoes and orthoses, are carried out. Walking tests are performed in comfortable clothing, as close to the body as possible, with uncovered legs (shorts). A walking frame is authorized for children who cannot walk 10 meters without one. The total duration of the assessment for the child is 20 minutes.

  3. 6-minute walk test

    Time frame: Inclusion, 10 weeks and 20 weeks

    Walking endurance is assessed by the 6-minute walking test (TDM6). According to the instructions for this test, the distance covered in 6 minutes is observed. Children are asked to walk as far as possible in 6 minutes on a 60-meter marked track in corridors. Children are fitted with shoes, orthoses and/or walking aids, depending on their habits. Footwear and technical aids must be identical between the 3 evaluation times T0, T1 and T2. An indication of the remaining test time is given to the children every minute by the investigator. The duration of the test for the child is estimated at 10 minutes.

  4. Motion control assessment

    Time frame: Inclusion, 10 weeks and 20 weeks

    Somatosensory function is measured by the cortico-cinematic coherence (CKC) index, which reflects the correlation between electrical activity in the primary sensorimotor cortex (measured by conventional low-density electroencephalogram (EEG)) and displacement of the center of pressure (CoP) in standing static equilibrium for 2 minutes (measured by a force platform). This exploratory index will enable us to estimate the cortical processing of proprioceptive afferents in the lower limbs. The estimated duration of this measurement is 10 minutes.

  5. Balance assessment

    Time frame: Inclusion, 10 weeks and 20 weeks

    Balance is assessed by 30-second unipodal hold tests (1 trial), if possible for the child, and 30-second bipodal hold tests under open-eye (1 trial), closed-eye (1 trial), foam (1 trial) and double-task conditions, i.e. counting backwards from 50 (1 trial). These tests are performed on a force platform (AMTI Accusway) to record the CoP's trajectory. The evaluation is scheduled to last 10 minutes.

  6. Assessment of gross motor functions for children with CP

    Time frame: Inclusion, 10 weeks and 20 weeks

    The GMFM-66 is a 66-item quantitative observational scale for assessing gross motor function in children with cerebral palsy (CP). Five dimensions of gross motor function are tested: Dimension A: lying and rolling, Dimension B: sitting, Dimension C: crawling and kneeling, Dimension D: standing, Dimension E: walking, running and jumping. Each item is scored on a 4-point scale, depending on whether the task requested by the investigator has been completed in full or in part. A maximum of three trials is allowed, and any spontaneous performance is accepted. The GMFM 66 takes around 45 minutes to complete.

  7. Assessment of gross motor functions for children with MNM

    Time frame: Inclusion, 10 weeks and 20 weeks

    For children with neuromuscular disorders (NMD), the Motor Function Measure (MFM). The MFM is a quantitative observational scale comprising 32 items, divided into 3 domains: domain D1: standing and transfer, domain D2: axial and proximal function, and domain D3: distal function. Each item assesses a specific motor task, and performance is rated on a scale from 0 to 3. The child is asked to perform the various MFM tasks. The MFM takes around 45 minutes to complete.

  8. Quality of life assessment

    Time frame: Inclusion, 10 weeks and 20 weeks

    Quality of life is assessed by the KIDSCREEN questionnaire. The KIDSCREEN-27 measures health-related quality of life in children and adolescents aged 8 to 18, across five dimensions: physical well-being, psychological well-being, autonomy and relationships with parents, social support and relationships with peers, and school environment. In this study, only the dimensions of physical well-being, psychological well-being, autonomy and relationships with parents are assessed. The questionnaire is completed by the child, unless under 8 years of age. Approximate completion time for children is 5 minutes.

  9. Assessment of daily activities and mobility

    Time frame: Inclusion, 10 weeks and 20 weeks

    Achievement of daily activities and mobility is assessed by the Pediatric Evaluation of Disability Inventory as a Computer Adaptive Test (PEDI-CAT). The PEDI-CAT measures the functional abilities of children with disabilities in four functional domains: activities of daily living, mobility, social and cognitive activities, and responsibility. The daily activities and mobility domains are assessed. The questionnaire is completed online during the consultation by the child accompanied by at least one parent. It takes approximately 15 minutes for the child to complete the questionnaire online.

  10. Actimetry

    Time frame: Inclusion, 10 weeks and 20 weeks

    Daily physical activity (PA) is measured using an actimeter (Actigraph GT3X). The following parameters are observed: number of daily steps, time spent at different levels of phsyical activity intensity (sedentary, light, moderate to vigorous), and time spent in different positions (lying, sitting, standing). The actimeter is worn on a belt during the day and on the wrist at night, for 7 consecutive days before or after each visit.

  11. User experience - User Experience Questionnaire

    Time frame: once at 20 weeks

    The short version of the User Experience Questionnaire (UEQ-S) is used. It contains 8 items grouped into two scales: pragmatic qualities (efficiency, insight, reliability) and hedonic qualities (stimulation, novelty). The format of the items is a semantic differential (e.g. Complicated - Simple) with a 7-point Likert scale. This questionnaire was chosen because it is the most widely used in the literature and has already been used with children.

  12. User experience - Usability Metric for User Experience

    Time frame: once at 20 weeks

    The Usability Metric for User Experience (UMUX) is a short 4-item questionnaire. The items are statements about ease of use and usefulness, with which respondents express agreement on a 7-point Likert scale. The UMUX is strongly correlated with the System Usability Scale (SUS), which is the most widely used usability questionnaire, with a large amount of associated research literature, but contains 10 items. The scores obtained on the UMUX are therefore used to position the solution's usability on the SUS interpretation scale ("worst imaginable", "poor", "acceptable", "good", 'excellent' or "best imaginable").

  13. User experience - Mobile Applications Rating Scale version utilisateur

    Time frame: once at 20 weeks

    The MARS (Mobile Applications Rating Scale user version) comprises 23 items divided into 6 domains. We will examine the first 3 domains: engagement, functionality and aesthetics. Answers are given on 5-point Likert scales.

Study contacts

Contact information is provided by the study sponsor or research team.

Mickaël DINOMAIS, MD

CONTACT

[email protected]

+ 33 2 41 35 52 67 ext. + 33

Sponsors and collaborators

Lead sponsor

University Hospital, Angers

Other Gov

Registry information

Acronym: EMMVIES

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Jun 15, 2025
Registry last updated
Dec 31, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.